CGS reimbursement alerts

This final LCD from CGS (J15) governs coverage criteria for external ocular photography services in Kentucky and Ohio, effective September 3, 2026. It establishes the medically necessary indications,

This proposed LCD from CGS (J15) addresses coverage criteria for genome-wide molecular methodologies detecting copy number alterations and structural variants in hematologic neoplasms across Kentucky

This proposed LCD from CGS (J15) addresses coverage of transcriptional biomarkers used for therapeutic decision-making in renal carcinoma, applicable to Part A and Part B in Kentucky and Ohio. As a dr

This proposed LCD from CGS (J15) addresses coverage criteria for next-generation sequencing (NGS) used in diagnosing and managing hematologic malignancies in Kentucky and Ohio under both Part A and Pa

This final LCD from CGS (J15) establishes coverage criteria for genetic testing related to hereditary thrombophilia under the MolDX program, effective October 12, 2026, for Kentucky and Ohio providers

This final LCD from CGS (J15) establishes coverage criteria for non-next generation sequencing targeted molecular panel tests used to guide targeted therapy decisions in cancer patients in Kentucky an

CGS (J15) is finalizing coverage policy for allergy diagnostic testing in Kentucky and Ohio, effective October 4, 2026. As a Final LCD, the comment period has closed, but providers should review cover

This final LCD from CGS (J15) governs molecular testing for solid organ allograft rejection in Kentucky and Ohio, effective August 30, 2026. It establishes coverage criteria and documentation requirem

LCD L40199 covers MolDX biomarker testing for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), effective 08/10/2026 under C

The final LCD L39658 addresses the use of molecular biomarkers for risk stratification of indeterminate pulmonary nodules following bronchoscopy, effective from June 18, 2026. Healthcare providers in

This final LCD from CGS (J15) governs coverage of temporary nontherapeutic ambulatory cardiac monitoring devices in Kentucky and Ohio, effective June 28, 2026. It establishes the indications, document

The proposed LCD on non-next generation sequencing tests for diagnosing BCR-ABL negative myeloproliferative neoplasms may lead to changes in reimbursement policies and coverage determinations, impacti

The proposed LCD for Fluid Jet System in treating BPH could lead to supports compliance with updated rates potential for urologists, provided the service aligns with Medicare's coverage guidelines. Ensuring proper d

The proposed LCD for Superficial Radiation Therapy (SRT) may impact billing by clarifying coverage terms for treatment of Nonmelanoma Skin Cancers (NMSC). This requires billing team review

The proposed LCD for MolDX biomarker testing in DCIS could impact billing by establishing clear criteria for reimbursement, potentially increasing the number of eligible tests approved for coverage. T

The proposed Local Coverage Determination (LCD) for molecular testing related to solid organ allograft rejection could significantly influence billing practices for relevant tests. With proper coding,

The proposed Local Coverage Determination (LCD) for External Infusion Pumps may impact billing by clarifying coverage criteria which providers must meet. This could potentially lead to an increase in

The proposed Local Coverage Determination (LCD) for Knee Orthoses may have significant implications on billing for orthopedic practices. If implemented, providers may need to adjust their claims submi

The proposed Local Coverage Determination (LCD) for genetic testing related to hereditary thrombophilia could significantly impact claims processing and reimbursement rates for genetic tests in this a

The proposed LCD on non-next generation sequencing targeted molecular panel tests may significantly impact billing practices for oncology providers. By establishing guidelines for which tests are elig

The proposed LCD for biomarker testing may significantly impact billing practices for metabolic liver disease services. Providers will need to ensure they are compliant with the new testing requiremen

The proposed Local Coverage Determination (LCD) for Urological Supplies may significantly impact billing processes for providers within the urology specialty. It is essential to assess current billing

The proposed Local Coverage Determination (LCD) for nebulizers may impact billing practices by clarifying coverage guidelines for these devices. This could lead to changes in reimbursement rates or el

The proposed Local Coverage Determination (LCD) for Peripheral Nerve Blocks and Procedures for Chronic Pain may significantly impact billing procedures for Pain Management specialists. Proper coding a

The proposed LCD for Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices may impact billing by providing clearer guidelines for reimbursement. This could facilitate appropriate claims submi

The proposed LCD for automated MRI detection and quantification could streamline billing for neurology services, potentially improving efficiency and accuracy in claims processing. This could lead to

The proposed LCD for Total Joint Arthroplasty may impact the coverage and reimbursement rates for providers performing this procedure. Ensuring compliance with new guidelines and requisite documentati

The proposed Local Coverage Determination (LCD) for Allergy Diagnostic Testing may have a significant impact on billing practices by clarifying coverage criteria and coding requirements for these test

The proposed LCD for Power Mobility Devices by CGS may significantly alter the reimbursement landscape for suppliers and providers. With clarity on the coverage criteria, healthcare professionals will

The proposed LCD on wheelchair options and accessories will likely affect billing practices by clarifying coverage and reimbursement policies for these items. This may lead to an increase in claims fo

The introduction of the MolDX Melanoma Risk Stratification Molecular Testing is expected to enhance precision in melanoma diagnostics, potentially leading to more tailored treatment plans. Providers s

The upcoming LCD on genetic testing for heritable thoracic aortic disease may streamline billing processes for such tests, ensuring better reimbursement for providers. This could lead to increased acc

The implementation of the MolDX molecular testing for solid organ allograft rejection will enhance the ability to detect potential organ rejection, impacting billing through the adoption of new HCPCS

The LCD outlines coverage for non-next generation sequencing tests for diagnosing BCR-ABL negative myeloproliferative neoplasms, which may significantly influence reimbursement policies. Providers wil

The MolDX policy for molecular biomarker testing could significantly impact reimbursement for targeted therapy selection in Rheumatoid Arthritis. As this policy becomes effective, providers may need t

The introduction of LCD for HLA-DQB1*06:02 testing for narcolepsy may affect billing practices by requiring updated coding and documentation specific to the new guidelines. Providers will need to fami

The new LCD regarding Routine Foot Care and Debridement of Nails may result in changes to reimbursement practices for podiatric services. Podiatrists should familiarize themselves with the updated gui

The implementation of the new LCD for SCODI may impact billing procedures and reimbursement rates for ophthalmic diagnostic imaging. Practices should review the updated guidelines closely to ensure co

The upcoming LCD for Speech-Language Pathology by CGS, effective from 08/07/2025, will introduce new guidelines that may affect reimbursement rates. Practices should prepare for potential changes in c

The implementation of the new LCD on Vitamin D Assay Testing will impact billing practices significantly. Providers will need to familiarize themselves with the new guidelines to ensure appropriate re

The LCD on Hospice Determining Terminal Status will impact billing practices by clarifying eligibility criteria for hospice services. This could lead to adjustments in claims submission and documentat

The new LCD for Physical Therapy in Home Health set to take effect on 08/07/2025 may lead to changes in billing protocols that could impact reimbursements. Providers will need to ensure compliance wit

The introduction of the LCD for Computed Tomography Cerebral Perfusion Analysis (CTP) requires billing team review. It allows for clearer guidelines on reimbursem

The off-label use of Rituximab and its biosimilars may lead to supports compliance with updated rates process, as insurers may require more documentation to justify its medical necessity. Providers sho

The new Local Coverage Determination (LCD) for RAST type tests may lead to increased scrutiny on claims related to allergy testing. Providers should prepare for potential impacts on reimbursement and

The new Local Coverage Determination (LCD) for the removal of benign skin lesions by CGS may impact billing practices in dermatology, leading to increased scrutiny on claims for these procedures. Prov

The implementation of the MGMT Promoter Methylation Analysis LCD may significantly affect billing practices for molecular diagnostics in oncology. Providers will need to ensure compliance with the new

The introduction of the MolDX: Molecular Diagnostic Tests policy will significantly impact billing practices for molecular diagnostics, potentially leading to changes in reimbursement rates. It is cru

The introduction of next-generation sequencing for solid tumors under the MolDX program may enhance the precision of diagnostics and treatment plans, positively impacting patient outcomes. However, pr

The MolDX: NRAS Genetic Testing LCD by CGS, effective from 08/21/2025, may significantly impact billing practices for genetic testing in oncology. Providers will need to familiarize themselves with th